{"id":"asp6294","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the PI3K delta subunit, ASP6294 is expected to modulate immune cell function and potentially treat various immune-related disorders.","oneSentence":"ASP6294 is a small molecule inhibitor of the PI3K delta subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:32.603Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT03282318","phase":"PHASE2","title":"A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2017-09-28","conditions":"Bladder Pain Syndrome, Interstitial Cystitis","enrollment":119},{"nctId":"NCT02681861","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2016-01","conditions":"Healthy Subjects, Pharmacokinetics of ASP6294","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ASP6294","genericName":"ASP6294","companyName":"Astellas Pharma Europe B.V.","companyId":"astellas-pharma-europe-b-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASP6294 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsing multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}